Advertisement
Advertisement
KYTX
Kyverna Therapeutics, Inc. Common Stock
10.78
USDSponsored
+0.55
+5.38%
May 13, 16:00 UTC -4
Closed
Pre-Market
10.89
+0.11
+1.01%
KYTX Earnings Reports
Positive Surprise Ratio
KYTX beat 6 of 9 last estimates.
67%
Next Report
Next Week
Date of Next Report
May 19, 2026
Estimate for Q1 26 (Revenue/ EPS)
--
/-$0.76
Implied change from Q4 25 (Revenue/ EPS)
--
/-5.00%
Implied change from Q1 25 (Revenue/ EPS)
--
/-26.21%
Kyverna Therapeutics, Inc. Common Stock earnings per share and revenue
On Mar 26, 2026, KYTX reported earnings of -0.80 USD per share (EPS) for Q4 25, beating the estimate of -0.87 USD, resulting in a 8.62% surprise. Revenue reached --, compared to an expected --, with a 0.00% difference. The market reacted with a -2.86% price change (close before vs. close after earnings).
Looking ahead to Q1 26, 6 analysts forecast an EPS of -0.76 USD, with revenue projected to reach -- USD, implying an decrease of -5.00% EPS, and increase of 0.00% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Kamada Ltd
Report Date
May 13, 2026 For Q1 26
Estimate
$0.11
Actual
$0.07
Surprise
-40.32%
Abeona Therapeutics Inc. Common Stock
Report Date
May 13, 2026 For Q1 26
Estimate
-$0.36
Actual
-$0.30
Surprise
+17.31%
Milestone Pharmaceuticals Inc. Common Shares
Report Date
May 13, 2026 For Q1 26
Estimate
$0.31
Actual
-$0.20
Surprise
-163.94%
Spero Therapeutics, Inc. Common Stock
Report Date
May 13, 2026 For Q1 26
Estimate
-$0.18
Actual
-$0.13
Surprise
+29.19%
Equillium, Inc. Common Stock
Report Date
May 13, 2026 For Q1 26
Estimate
-$0.04
Actual
-$0.06
Surprise
-34.53%
Spruce Biosciences, Inc. Common Stock
Report Date
May 13, 2026 For Q1 26
Estimate
-$8.99
Actual
-$8.94
Surprise
+0.58%
BeyondSpring Inc. Ordinary Shares
Report Date
May 13, 2026 For Q1 26
Estimate
-Actual
-$0.05
Surprise
-
Tango Therapeutics, Inc.
Report Date
May 13, 2026 For Q1 26
Estimate
-$0.31
Actual
-$0.32
Surprise
-0.13%
Longeveron Inc. Common Stock
Report Date
May 13, 2026 For Q1 26
Estimate
-$0.16
Actual
-$0.19
Surprise
-12.89%
Bionano Genomics, Inc. Common Stock
Report Date
May 13, 2026 For Q1 26
Estimate
-$0.96
Actual
-$0.76
Surprise
+21.57%
FAQ
What were Kyverna Therapeutics, Inc. Common Stock's earnings and revenue for the latest quarter Q4 2025?
For Q4 2025, Kyverna Therapeutics, Inc. Common Stock reported EPS of -$0.80, beating estimates by 8.62%, and revenue of $0.00, 0% as expectations.
How did the market react to Kyverna Therapeutics, Inc. Common Stock's Q4 2025 earnings?
The stock price moved down -2.86%, changed from $8.03 before the earnings release to $7.80 the day after.
When is Kyverna Therapeutics, Inc. Common Stock expected to report next?
The next earning report is scheduled for May 19, 2026.
What are the forecasts for Kyverna Therapeutics, Inc. Common Stock's next earnings report?
Based on 6
analysts, Kyverna Therapeutics, Inc. Common Stock is expected to report EPS of -$0.76 and revenue of -- for Q1 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement